<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Cymabay PBC Interactive</title>
    <Link rel="stylesheet" href="./style.css">
    <script src="./script.js" defer></script>
</head>
<body>
    <div class="launch-UI" id="launch-UI">
        <div class="launch-UI-title" id="launch-UI-title">
            Cymabay PBC Interactive
        </div>
        <button class="resume-btn" id="resume-btn">
            Resume
        </button>
        <button class="restart-btn" id="restart-btn">
            Restart
        </button>
    </div>

    <div class="main-container" id="main-container">
        <div class="form-container" id="form-container">

            <div class="home-left-column" id="home-left-column"></div>

            <div class="about-left-column hidden" id="about-left-column">
                <div class="company-logo"></div>
                <p>
                    <strong>
                        At CymaBay, we are committed to improving the<br>
                        lives of patients with liver and other chronic<br>
                        diseases by developing and providing access to<br>
                        innovative therapies
                    </strong>
                        . Our evidence-based decision<br>
                        making and commitment to the highest quality<br>
                        standards reflect our relentless dedication to the<br>
                        patients, families and communities we serve.
                </p>
                <a href="https://cymabay.com/" target="_blank">Learn More</a>
            </div>

            <div class="EASL-presentations hidden" id="EASL-presentations">
                <div class="company-logo"></div>
                <div class="EASL-presentation-container">
                    <div class="EASL-left"></div>
                    <div class="EASL-middle"></div>
                    <div class="EASL-right"></div>
                </div>
            </div>

            <div class="right-column" id="right-column">
                <ul class="btn-container">
                    <li><span class="btn-arrow"></span><button class="about-us" id="about-us">About us</button></li>
                    <li><span class="btn-arrow"></span><button class="EASL-btn" id="EASL-btn">EASL 2022 presentations</button></li>
                    <li><button>What do you know about PBC? <br>Take this shorut quiz and weâ€™ll
                        donate $50 to patient advocacy.</button></li>
                    <li><span class="btn-arrow"></span><button class="clinical-trial-btn" id="clinical-trial-btn">Clinical trials</button></li>
                    <li><button>Request info</button></li>
                </ul>
            </div>

            <div class="clinical-trials hidden" id="clinical-trials">
                <div class="company-logo"></div>
                <div>Ongoing clinical trials</div>
                <div class="clinical-text-box-container">
                    <div class="clinical-text-box">
                        <p>
                            RESPONSE: Response to
                            Seladelpar in Subjects With
                            Primary Biliary Cholangitis
                            (PBC) and Inadequate Control
                            to or an Intolerance to
                            Ursodeoxycholic Acid (UDCA)
                            (Phase 3)
                        </p>
                        <div><a href="https://clinicaltrials.gov/ct2/show/NCT04620733?term=seladelpar">View on clinicaltrials.gov &gt;</a></div>
                        <div><a href="https://www.pbcstudies.com/">Learn more at pbcstudies.com &gt;</a></div>
                    </div>
                    <div class="clinical-text-box">
                        <p>
                            HEPATIC IMPAIRMENT: An Open-Label
                            Study Following Oral Dosing of
                            Seladelpar to Subjects With
                            Primary Biliary Cholangitis
                            (PBC) and Hepatic Impairment
                            (HI) (Phase 1)
                        </p>
                        <div><a href="https://clinicaltrials.gov/ct2/show/NCT04620733?term=seladelpar">View on clinicaltrials.gov &gt;</a></div>
                    </div>
                </div>
                <div class="clinical-footer">
                    <p>
                        Want to become a study site for
                        future trials or learn more<br>
                        about these trials? Have a
                        patient who may be
                        appropriate? <br>
                        Talk with Medical Information or<br>
                        <button>fill out this form.</button>
                    </p>
                </div>
            </div>

            
        </div>
    </div>
</body>
</html>